Information Provided By:
Fly News Breaks for September 27, 2019
Sep 27, 2019 | 07:15 EDT
JPMorgan analyst Tycho Peterson downgraded Accelerate Diagnostics to Underweight from Neutral with an unchanged price target of $16. Following the release of "disappointing" results from the Mayo/UCLA study, the company's full-year system placement goal is looking "increasingly ambitious," Peterson tells investors in a research note. The analyst sees risk to Accelerate's near- to intermediate-term outlook and sees better risk/reward opportunities elsewhere.
News For AXDX From the Last 2 Days
There are no results for your query AXDX